Curis, Inc.

Oxagen Limited

Hoffmann-la Roche Inc.

Pfizer Italia S.r.l.

Genentech, Inc.

Asterand UK Limited

Merck + Co., Inc.

Pharmagene Laboratories Limited

Evotec Oai

Curtis, Inc.

Pharmacia Italia S.p.a.

Atopix Therapeutics Limited

Dania Tesei

Katia Martina

Matteo D'anello

Edward Andrew Boyd

Stephen Colin Price

Oivin M Guicherit

Frederick Arthur Brookfield

Lee L Rubin

Anthony David Baxter

Mark Richard Ashton

Shirley Ann Brunton

John Harry Alexander Stibbard

Mark Whittaker

Eric Roy Pettipher

David Middlemiss

Michael George Hunter

Chris Palmer

Alexander W Oxford

Maria Gabriella Brasca

George Hynd

Jonathan Mark Sutton

David Edward Clark

Kenneth Lyle Clark

Matteo D'Anello

Robert Alexander Coleman

Garry Fenton

Richard Jon Davis

Neil Victor Harris

Barbara Salom

William John Trigg

Keith Alfred James Stuttle

Patrizia Giordano

Jonathan Anthony Larard

Maria Frank-Kamenetsky

Wolfgang Von Der Saal

Jeffrey A Porter

Jonathan Gridley

Jeffery Porter

Raymond Lau

Colin H Mackinnon

Stefan Scheiblich

Francesco Angelucci

Ulrike Reiff

Georg Tiefenthaler

Manfred Kubbies

Judith Helen Boyd, Legal Representative

Timothy Woodcock

Guy Georges

Michael H Fisher

William H Parsons

Matthias Koerner

Peter T Meinke

Konrad Honold

Petra Rueger

Stefan Weigand

Matthias Rueth

Maria L Garcia

Gregory J Kaczorowski

Thomas Von Hirschheydt

Richard Edward Armer

Bernhard Goller

Justin Warne

Christine Schuell

John Stibbard

Lee D Rubin

Sabine Huensch

Philip Andrew Hay

Christopher Palmer

Mick Hunter

William John Evotec Oai Trigg

The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS.and. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.

Small organic molecule regulators of cell proliferation

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

Mediators of hedgehog signaling pathways, compositions and uses related hereto

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

Mediators of hedgehog signaling pathways, compositions and uses related thereto

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The present invention provides indole derivatives that antagonize prostaglandin D, and that can be used to treat inflammatory diseases mediated by prostaglandin D.

Treatment of CRTH2-mediated diseases and conditions

Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors

Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: Ris an optionally substituted Caryl or Calkyl group; L' is a single bond, &#x2014;O&#x2014; or &#x2014;C(&#x2550;O)&#x2014;; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR; S and CR; NH and CR; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where Ris selected from fluoro and chloro; and Ris either: (i) &#x2014;COH; (ii) &#x2014;CONH; (iii) &#x2014;CH&#x2014;OH; or (iv) tetrazol-5-yl. 

[object Object]

1-acetic acid-indole derivatives with PGD2 antagonist activity

Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors

Growing community of inventors

Berkshire, United Kingdom

Edward Andrew Boyd